MCL Literature Feed

This review highlights that TP53-mutated MCL represents a distinct high-risk entity with poor outcomes to chemoimmunotherapy, underscoring the urgent need for novel, non-chemotherapy frontline approaches in these patients.

Reviewing the TRIANGLE trial, this paper argues that adding ibrutinib to frontline induction makes omitting autologous stem cell transplant consolidation a non-inferior, less toxic option for young patients.

This review outlines the clinical landscape and practical application of CAR-T and bispecific antibodies for relapsed/refractory MCL, guiding their integration into practice after targeted therapy failure.

This case report and literature review details the diagnosis and management of central nervous system involvement in MCL, a rare and aggressive manifestation with a poor prognosis.

This review details Bortezomib's multiple anti-cancer mechanisms and significant toxicities, highlighting the need for next-generation proteasome inhibitors with better therapeutic windows for treating mantle cell lymphoma.

This review synthesizes the evolution of BTK-targeted therapies, from covalent inhibitors to non-covalent agents and degraders, outlining current treatment paradigms and future combination strategies for frontline and relapsed MCL.

Reviewing AIM and SYMPATICO trials, the ibrutinib-venetoclax combination shows high efficacy in relapsed/refractory MCL, supporting a potential fixed-duration, MRD-guided treatment strategy.

This review summarizes the clinical development and efficacy of BTK inhibitors in MCL, detailing common resistance mutations and outlining future directions for this crucial targeted therapy class.

The first approval of odronextamab, a CD20xCD3 bispecific antibody, in other lymphomas introduces a promising off-the-shelf, T-cell engaging immunotherapy for potential use in relapsed/refractory MCL.

This review confirms MRD's strong prognostic value in MCL but cautions that technical limitations and the uncertain clinical significance of low-level disease currently prevent its routine use for treatment decisions.

This review summarizes the established efficacy and toxicities of CD19 CAR-T therapy in B-cell lymphomas, including MCL, while highlighting future research directions like novel targets and sequencing with bispecifics.

MCL can relapse late as isolated soft tissue tumors in the extremities, a rare clinical presentation clinicians must recognize for timely diagnosis, even without concurrent nodal disease.

This review highlights that excellent outcomes with modern frontline chemo-immunotherapy plus BTK inhibitors are challenging the traditional role of autologous transplant consolidation in mantle cell lymphoma.

This review positions pirtobrutinib, a non-covalent BTKi, as a highly effective and safe treatment for relapsed/refractory MCL, especially for patients who have progressed on prior covalent BTK inhibitors.

The non-covalent BTK inhibitor pirtobrutinib shows a 58% overall response rate in relapsed/refractory MCL, providing a crucial new option for patients previously treated with covalent BTK inhibitors.

This review synthesizes current data and practical considerations for CAR-T and bispecific antibodies, guiding clinical decision-making and sequencing for these T-cell engaging therapies in relapsed/refractory MCL.

This review explores CAR-NK cells as a promising alternative to CAR-T therapy for mantle cell lymphoma, potentially offering comparable efficacy with a significantly improved safety profile and fewer severe toxicities.

This CML review details targeting the ubiquitin-proteasome system to overcome TKI resistance, offering a potential mechanistic strategy for addressing BTKi resistance in MCL.

This review synthesizes current and emerging therapies for relapsed/refractory MCL, including BTKi, BCL2i, CAR-T, and bispecifics, emphasizing the evolving challenge of post-BTKi treatment sequencing.

A rare case of mantle cell lymphoma discovered incidentally within a benign Warthin tumor highlights a diagnostic pitfall, underscoring the need to pathologically evaluate lymphoid stroma to avoid missed diagnoses.

This review summarizes the evolving treatment landscape for relapsed/refractory MCL, highlighting survival gains from BTKi and CAR-T and outlining emerging therapies like bispecifics for multiply-refractory patients.

This paper outlines the diagnostic and treatment challenges of rare ocular and nasopharyngeal MCL, highlighting the necessity of a multidisciplinary approach for managing these extranodal presentations.

This review summarizes how molecular profiling (e.g., TP53) and MRD are reshaping MCL therapy by integrating novel agents into frontline care, personalizing treatment, and improving high-risk patient outcomes.

This review explains MCL's clinical heterogeneity through distinct molecular subtypes and genomic alterations like TP53, which serve as key prognostic biomarkers and guide development of novel therapies.

This commentary evaluates rituximab's evolving role in MCL, questioning its necessity in modern chemo-free regimens and its place alongside novel targeted agents.

This review highlights BTK's non-catalytic scaffolding function as a novel mechanism of BTKi resistance, presenting a new therapeutic target beyond kinase inhibition for treating B-cell lymphomas like MCL.

This review synthesizes current knowledge on MCL genetic markers, advocating for a personalized medicine approach that integrates molecular profiles like TP53 to improve risk stratification and guide therapy.

The non-covalent BTK inhibitor pirtobrutinib demonstrates efficacy in mantle cell lymphoma patients who have progressed on prior covalent BTKi therapy, overcoming a common resistance mechanism.

A case of primary ocular adnexal MCL demonstrates its potential for rapid systemic progression, emphasizing the need for thorough initial staging and aggressive systemic therapy despite localized presentation.

This review summarizes the clinical data and rationale for targeted agents like BTK and BCL2 inhibitors, highlighting the paradigm shift away from chemotherapy in both relapsed/refractory and frontline MCL.